While RVS program is the closest to being an approved product, I am pleased about developments in the anti-HBV program. I am also pleased to hear that ENTA is getting closer to selecting anti-Covid-19 drugs, and that their approach is to attack the virus polymerase and virus protease rather than using an entry inhibitor. I know some expressed disappointment that the pace of development wasn't faster but ENTA has great expertise in antivirals and i is better to take a bit longer to generate a better drug. Both drugs are being designed to be orally administered and the idea is that someone beginning to show symptoms or testing positive would get a prescription and begin taking tablets that they can take everyday for a specified time frame. Still a long way to go but the approach sounds really smart.
News 
Market Data 
Discover 
